Semnur Pharmaceuticals, Inc.
corporate_fare Company Profile
Semnur Pharmaceuticals, Inc. (OTC:SMNR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for SMNR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for SMNR spans 10-Q, 424B3, 8-K, SCHEDULE 13D/A.
Recent high-impact activity:
- Semnur Q3 10-Q: $54K Cash, Going Concern Doubt, $100M iHolding Deal Still Unsigned
- Semnur Q2 2026: $39k Cash, Going Concern Warning, and a $100M Lifeline Term Sheet
- Semnur Secures Binding Term Sheet for $100M Strategic Investment at $10.00/Share
- Semnur Pharmaceuticals Secures $100M Equity Investment at $10/Share, 16x Current Price
- Semnur Pharmaceuticals Secures Binding Term Sheet for $100M Investment at Significant Premium
Financial Snapshot
Short Interest & Short Volume
12.89 days to coverFINRA reported short interest of 83,453 shares in SMNR as of the October 30, 2026 settlement, unchanged from the prior period — about 12.9 days to cover at its recent average daily volume. On November 20, 2026, 8.0% of SMNR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for SMNR, detected from its recent SEC filings · based on capital-structure filings through 2026-07-07.
Strategic Investment Secured · Significant Premium Pricing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →